CHEMICAL MANAGEMENT

WHAT NEXT FOR THE CHEMICAL INDUSTRY?

September 22, 2022

WHAT NEXT
Chemical companies today are experiencing unexpected economic scenarios. This has required them to adapt to rapidly changing supply & demand and adjust workplace structures to ensure the health & safety of their workers.

Spotlight

Supernus Pharmaceuticals, Inc.

Pioneering New Medicines in Neurology and Psychiatry With more than 20 years of experience, we are a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) disorders. In 2013 we launched Oxtellar XR® and Trokendi XR®, two novel neurology products for the treatment of epilepsy. We are also developing several product candidates in psychiatry to address unmet medical needs and opportunities in attention-deficit hyperactivity disorder (ADHD) and its coexisting disorders, and depression. We are developing differentiated products by leveraging our proprietary and in-licensed technologies. We use such technologies to discover and develop novel uses for known drug compounds and to enhance their therapeutic benefits. Our focus on known drug compounds with established mechanisms of action reduces the risks, costs, and time typically associated with pharmaceutical product development.

OTHER WHITEPAPERS
news image

Ensuring Compliance with ASTM STANDARDS for Mechanical Testing of Plastics and Composites

whitePaper | June 24, 2022

The performance of CFRPs depends on the fiber strength, the filling ratio of the carbon fibers in the resin and the orientation of the carbon fibers. For these reasons, CFPRs exhibit highly anisotropic mechanical behavior. Specialized

Read More
news image

Hydrogen policy gap

whitePaper | August 10, 2022

The early days of the decarbonised hydrogen industry is seeing a gap emerging between Europe and the US for low-carbon (blue) hydrogen.

Read More
news image

AEROMMA 2022 whitepaper

whitePaper | July 9, 2022

Recent National Oceanic and Atmospheric Administration (NOAA) Chemical Sciences Laboratory (CSL) science foci are also current topics that have generated broad interest in the atmospheric science,

Read More
news image

Chemical Industry Growth in a Circular Economy

whitePaper | November 20, 2019

While sustainability has long been on the chemical industry agenda, the value paradigm is shifting fast. By capturing a share of this rapidly expanding market for reusable, renewable and recyclable products, chemical companies can turn these changes to their advantage and drive growth while helping to shape a greener, cleaner, more sustainable future.

Read More
news image

Tech Trends 2022

whitePaper | December 21, 2022

Over the past two years, the world has been reeling from the shock of the pandemic, and we are now collectively trying to navigate to our “next normal.” Those of us on the Tech Trends team believe that this represents the opportunity to engineer a better future—not to just.

Read More
news image

Optimizing Carbon Capture, Utilization and Storage to Meet Ambitious Sustainability Goals

whitePaper | October 5, 2022

The race to a zero carbon future is on. Global oil and gas, petrochemical and chemical companies alike have announced ambitious and broad carbon mitigation.

Read More

Spotlight

Supernus Pharmaceuticals, Inc.

Pioneering New Medicines in Neurology and Psychiatry With more than 20 years of experience, we are a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) disorders. In 2013 we launched Oxtellar XR® and Trokendi XR®, two novel neurology products for the treatment of epilepsy. We are also developing several product candidates in psychiatry to address unmet medical needs and opportunities in attention-deficit hyperactivity disorder (ADHD) and its coexisting disorders, and depression. We are developing differentiated products by leveraging our proprietary and in-licensed technologies. We use such technologies to discover and develop novel uses for known drug compounds and to enhance their therapeutic benefits. Our focus on known drug compounds with established mechanisms of action reduces the risks, costs, and time typically associated with pharmaceutical product development.

Events